## **CLAIMS ONLY**

10634034 FEB APPLICATION OF THE STATE OF THE

CLNMS

							CLAMS				14 14			
	ASF	KED.	AF	AFTER 1st AMENDWENT		AFTER 2nd AMEROWENT				·		<u> </u>		
	MO.	DCP.	<b>●</b> Ø.	DCP.	DrO.	DCP.	1 1		#4O.	оср.	b40.	DCP.	Deta.	00
			_				1 [	51		l	]			
1			├				1 [	62			<u> </u>	<u> </u>	<u> </u>	
2				<del></del>		· · · · · · ·		53			<u> </u>	<u> </u>	<u> </u>	
-4				<del>   -</del>				54	<u> </u>		<u> </u>		<b> </b>	
				<del>                                     </del>		i — — —		65			ļ		<b> </b>	
5				<u> </u>			1	56			<u> </u>			L
6			-					57					<b>!</b>	
7 8				-				83		<u>.</u>	<b></b>			
9				<del> </del>				59			<b> </b>			_
10				F				မ						
11				<del>                                     </del>			i [	61						
12			<del></del>					62			<u> </u>			_
								ន						
13				-1-				64						
15				- -				<b>6</b> 5						
				-				66						
16				1				67						
17								68						
19	- · <b></b> -¦			1				8						<u>.</u>
							-{_	70						
20								71						
22								72						
23								73						
24								74						
25								75					· -	
26	<del></del>	-						76						
27								77						
28								78						
29								79						
30	-							80						
31							_	81						
32								82						
33							1	83						
34		-						84						
35								85						
36		$\neg \neg$						<b>e</b> 5						
37							<b>1</b>	87						
38		-					<u> </u>	83						
39								89						
40		$\neg \neg$					<b>—</b>	90						
41			-					91						
42							1	82						
43							l	93						
44							<u> </u>	94						
45								95						_
46							<u> </u>	96						
47	+				·		<u> </u>	97			<u></u> ∤	<del></del> -		
48						]	<u> </u>	98						
49						]	<b>1</b> —	99					<del> </del>	
50								100			<del></del> -			
LATO			0	1		1	TC	TAL NO.	1	1	]	_!		4
DO.			3	-		<b></b>	7	OTAL XP.		-				
OEP.		17(3)	1 64			250	1					CHA!		4.6

\*MAY BE USED FOR ADDITIONAL CLAUMS OR ADMENDMENTS

U.S.DEPARTIMENT OF COMMERCE Patient and Trademark Office

FORM PTO-2022 (1-00)

1/3. CPO. 1996-643-69398153

. وکیسته